MEK-162 (Array BioPharma Inc.)is a selective non-ATP-competitive MEK inhibitor initially developed as an anti-rheumatoid arthritis drug due to its profound inhibitory effects on the NF-κB pathway leading to decreased IL-1, IL-6 and TNF activities [7]. Here, MAP2K7 is linked to rheumatoid arthritis.